(2008). A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.
(1986). Brandriss MW: Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies.
(2007). Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches.
(1992). Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.
(2001). Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops.
(1996). Conformational studies of a short linear peptide corresponding to a major conserved neutralizing epitope of human respiratory syncytial virus fusion glycoprotein. Biopolymers
(2007). Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.
(2003). EP: Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol
(2007). Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
(2001). Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.
(2001). Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology
(1999). JT: Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.
(1979). Lymphotropic papovaviruses isolated from African green monkey and human cells. Med Microbiol Immunol (Berl)
(1998). Melero JA: Antigenic structure of human respiratory syncytial virus fusion glycoprotein.
(1983). Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol
(2002). Proof of Principle Study Investigators: A controlled trial of a human papillomavirus type 16 vaccine.
(2001). Reichman RC: A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.
(1990). Reichman RC: Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles.
(1994). Reichman RC: Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles.
(1993). RL: Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles.
(1997). RL: Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly.
(1998). RL: Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.
(2001). RL: Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.
(2002). SC: Atomic model of the papillomavirus capsid.
(1998). Suzich JA: Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.